GlassScriptPhysician profile
Charles Wang
NPI 1275202764
$658.77
in general payments reported to CMS, 2019-2025
11 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $74.75 · 2024: $215 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $187.32 | 2022 | |
| Abbott Laboratories | $181.28 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $111.97 | 2024 | Austedo Xr |
| Mallinckrodt Hospital Products INC. | $40.48 | 2023-2024 | Acthar |
| Heron Therapeutics, INC. | $24.46 | 2024 | Zynrelef |
| Aurinia Pharma U.S., INC. | $21.72 | 2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $21.52 | 2024 | |
| Calliditas Therapeutics US INC. | $19.83 | 2023 | Tarpeyo |
| Lilly USA, LLC | $17.96 | 2024 | Zepbound, Mounjaro |
| Halozyme INC | $16.91 | 2023 | |
| Tandem Diabetes Care, INC. | $15.32 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.